106 related articles for article (PubMed ID: 2513082)
1. Differential effects of low-dose tissue plasminogen activator and streptokinase on platelet aggregation.
Berridge DC; Burgess-Wilson ME; Westby JC; Hopkinson BR; Makin GS
Br J Surg; 1989 Oct; 76(10):1026-30. PubMed ID: 2513082
[TBL] [Abstract][Full Text] [Related]
2. Effects of streptokinase, urokinase, and recombinant tissue plasminogen activator on platelet aggregability and stability of platelet aggregates.
Terres W; Umnus S; Mathey DG; Bleifeld W
Cardiovasc Res; 1990 Jun; 24(6):471-7. PubMed ID: 2167173
[TBL] [Abstract][Full Text] [Related]
3. Rapid dissociation of platelet-rich fibrin clots in vitro by a combination of plasminogen activators and antiplatelet agents.
Lam SC; Dieter JP; Strebel LC; Taylor TM; Muscolino G; Feinberg H; Le Breton GC
J Pharmacol Exp Ther; 1991 Dec; 259(3):1371-8. PubMed ID: 1762085
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the effects of streptokinase, t-PA and APSAC on human platelet aggregation in vitro in the absence and presence of aspirin.
Fears R; Ferres H; Greenwood HC
Thromb Res; 1990 Nov; 60(4):259-68. PubMed ID: 2128420
[TBL] [Abstract][Full Text] [Related]
5. Tissue-type plasminogen activator and streptokinase induce platelet hyperaggregability in the rabbit.
Ohlstein EH; Storer B; Fujita T; Shebuski RJ
Thromb Res; 1987 May; 46(4):575-85. PubMed ID: 3112993
[TBL] [Abstract][Full Text] [Related]
6. Platelet activation and subsequent inhibition by plasmin and recombinant tissue-type plasminogen activator.
Penny WF; Ware JA
Blood; 1992 Jan; 79(1):91-8. PubMed ID: 1530814
[TBL] [Abstract][Full Text] [Related]
7. In vitro effect of plasmin on human platelet function in plasma. Inhibition of aggregation caused by fibrinogenolysis.
Gouin I; Lecompte T; Morel MC; Lebrazi J; Modderman PW; Kaplan C; Samama MM
Circulation; 1992 Mar; 85(3):935-41. PubMed ID: 1531623
[TBL] [Abstract][Full Text] [Related]
8. Thrombolytic and antithrombotic efficacy of the platelet GPIIb-IIIa antagonist DMP728.
Mousa SA; Forsythe MS; Diemer M; Bozarth JM; Reilly TM
Coron Artery Dis; 1994 Nov; 5(11):919-27. PubMed ID: 7719524
[TBL] [Abstract][Full Text] [Related]
9. [Changes in oxidative stress and hemostatic parameters in the course of thrombolytic therapy of pulmonary embolism].
Mühl D
Orv Hetil; 2008 May; 149(20):935-48. PubMed ID: 18467263
[TBL] [Abstract][Full Text] [Related]
10. Temporal effects of thrombolytic agents on platelet function in vivo and their modulation by prostaglandins.
Rudd MA; George D; Amarante P; Vaughan DE; Loscalzo J
Circ Res; 1990 Nov; 67(5):1175-81. PubMed ID: 2146037
[TBL] [Abstract][Full Text] [Related]
11. Time course of platelet aggregation during thrombolytic treatment of massive pulmonary embolism.
Mühl D; Füredi R; Gecse K; Ghosh S; Falusi B; Bogár L; Roth E; Lantos J
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):661-7. PubMed ID: 17890954
[TBL] [Abstract][Full Text] [Related]
12. Streptokinase and rt-PA activate platelets by a different way: implications on the rethrombosis rate after their administration in myocardial infarction.
Parise P; Hauert J; Iorio A; Callegari P; Agnelli G
J Lab Clin Med; 1995 Feb; 125(2):212-21. PubMed ID: 7531212
[TBL] [Abstract][Full Text] [Related]
13. The potentiation of adrenaline-induced in vitro platelet aggregation by ADP, collagen and serotonin and its inhibition by naftopidil and doxazosin in normal human subjects.
Alarayyed NA; Graham BR; Prichard BN; Smith CC
Br J Clin Pharmacol; 1995 Apr; 39(4):369-74. PubMed ID: 7640142
[TBL] [Abstract][Full Text] [Related]
14. Effect of recombinant-tissue plasminogen activator, low molecular weight urokinase and unfractionated heparin on platelet aggregation.
Paolini R; Casonato A; Boeri G; Luzzatto G; Girolami A; Sasahara AA; Cella G
J Med; 1993; 24(2-3):113-30. PubMed ID: 8409776
[TBL] [Abstract][Full Text] [Related]
15. Streptokinase, but not tissue plasminogen activator, attenuates platelet aggregation in patients with acute myocardial infarction.
Karlberg KE; Chen J; Hagerman I; Bergström K; Wallin R; Saldeen T; Sylvén C
J Intern Med; 1993 Nov; 234(5):513-9. PubMed ID: 8228797
[TBL] [Abstract][Full Text] [Related]
16. Effects of imidazoline and non-imidazoline alpha-adrenergic agents on canine platelet aggregation.
Hikasa Y; Abe M; Satoh T; Hisashi Y; Ogasawara S; Matsuda H
Pharmacology; 1999 Apr; 58(4):171-82. PubMed ID: 10077736
[TBL] [Abstract][Full Text] [Related]
17. Possible mechanism of vascular reocclusion after initially successful thrombolysis with recombinant tissue-type plasminogen activator.
Yamada Y; Furui H; Furumichi T; Yamauchi K; Yokota M; Saito H
Am Heart J; 1991 Jun; 121(6 Pt 1):1618-27. PubMed ID: 1903579
[TBL] [Abstract][Full Text] [Related]
18. Relative importance of thrombin compared with plasmin-mediated platelet activation in response to plasminogen activation with streptokinase.
Winters KJ; Santoro SA; Miletich JP; Eisenberg PR
Circulation; 1991 Oct; 84(4):1552-60. PubMed ID: 1833087
[TBL] [Abstract][Full Text] [Related]
19. Regulation of human platelet activation--analysis of cyclooxygenase and cyclic AMP-dependent pathways.
Krishnamurthi S; Westwick J; Kakkar VV
Biochem Pharmacol; 1984 Oct; 33(19):3025-35. PubMed ID: 6091666
[TBL] [Abstract][Full Text] [Related]
20. Studies on the release of a plasminogen activator inhibitor by human platelets.
Kruithof EK; Tran-Thang C; Bachmann F
Thromb Haemost; 1986 Apr; 55(2):201-5. PubMed ID: 2940723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
